Cell and Gene Therapy Market to Reach US$ 105.83 Billion by 2033 at 21.5% CAGR, Driven by Advances in CAR-T, Gene Editing, and Rare Disease Treatments | DataM Intelligence

According to DataM Intelligence, the global Cell and Gene Therapy market reached US$ 13.90 billion in 2024 and is expected to reach US$ 105.83 billion by 2033, growing at a CAGR of 21.5% during the forecast period 2025-2033, driven by rapid progress in CAR-T cell therapies, CRISPR-based gene editing, expanding approvals for oncology and rare diseases, strong pipeline momentum, and increasing investment in manufacturing and commercialization.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/cell-and-gene-therapy-market?jd

Cell and Gene Therapy Market Key Mergers and Acquisitions

✦ January 2026: Novartis AG acquired a gene therapy biotech startup specializing in rare disease vectors to bolster its pipeline beyond Zolgensma and CAR-T therapies.
✦ December 2025: Gilead Sciences, Inc. (Kite Pharma) completed a strategic acquisition of a next-generation CAR-T platform company to enhance its oncology cell therapy offerings.
✦ November 2025: Vertex Pharmaceuticals Incorporated licensed a CRISPR-based editing technology from a gene editing innovator to advance its pipeline for genetic disorders and sickle cell disease.

Cell and Gene Therapy Market Key Industry Developments

☑️ January 2026: Novartis AG, Gilead Sciences, Inc., and Bristol Myers Squibb Company presented updated long-term data for CAR-T therapies (Kymriah, Yescarta, Breyanzi) in lymphoma and leukemia, supporting expanded indications and real-world evidence in oncology centers.
☑️ December 2025: Sarepta Therapeutics, Inc. and bluebird bio, Inc. advanced their gene therapy programs with new regulatory submissions and positive interim results for Duchenne muscular dystrophy and beta-thalassemia, targeting broader patient access.
☑️ November 2025: Amgen, Inc. and CSL Behring LLC expanded manufacturing capacity for cell and gene therapies, with new facilities focused on scalable production for rare diseases and hematologic conditions.

Purchase the report to unlock market insights:
https://www.datamintelligence.com/buy-now-page?report=cell-and-gene-therapy-market

Cell and Gene Therapy Market Segmentation Analysis

By Therapy Type: Cell Therapy holds the largest share due to dominant CAR-T approvals and commercial success in hematologic malignancies; Gene Therapy grows fastest with expanding CRISPR and viral vector-based treatments for rare genetic diseases, monogenic disorders, and muscular dystrophies.

By Application: Oncology dominates with the highest share driven by CAR-T therapies for lymphomas, leukemias, and multiple myeloma; Rare Diseases follow closely with gene therapies for inherited conditions; Musculoskeletal Conditions, Ophthalmology, Blood Disorders, Immunodeficiency Disorders, and Graft-versus-host disease (GVHD) grow steadily; Others include neurological and metabolic disorders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cell-and-gene-therapy-market?jd

Cell and Gene Therapy Market Key Players

✦ Novartis AG - In January 2026, acquired a gene therapy startup and presented updated Kymriah long-term data for pediatric ALL and DLBCL, expanding manufacturing and access programs globally.
✦ Gilead Sciences, Inc. (Kite Pharma) - Completed acquisition of a CAR-T platform company in December 2025 and advanced Yescarta and Tecartus with new combination trial readouts in lymphoma and leukemia.
✦ Bristol Myers Squibb Company - Rolled out expanded Breyanzi data in late 2025 for large B-cell lymphoma, with improved manufacturing scalability and regulatory progress in earlier lines.
✦ Vertex Pharmaceuticals Incorporated - Advanced its gene editing programs in December 2025 with positive data for sickle cell disease and beta-thalassemia, focusing on ex vivo CRISPR therapies.
✦ Sarepta Therapeutics, Inc. - Presented new clinical results in November 2025 for exon-skipping and gene therapy candidates in Duchenne muscular dystrophy, targeting broader mutation coverage and accelerated approval pathways.

Cell and Gene Therapy Market Regional Insights

North America dominates the Cell and Gene Therapy market with the largest revenue share, supported by high regulatory approvals (FDA), advanced cell therapy manufacturing infrastructure, strong reimbursement for high-cost treatments, significant R&D investment by leading biopharma companies, and widespread adoption in oncology and rare disease centers.

Asia-Pacific is the fastest-growing region, fueled by rising rare disease awareness, increasing clinical trial participation, expanding manufacturing capabilities in China and Japan, government support for advanced therapies, growing healthcare expenditure, and aggressive market entry by global players targeting oncology and genetic disorders.

Unlock 360° Market Intelligence with DataM Intelligence Subscription Services:
https://www.datamintelligence.com/reports-subscription?jd

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.